Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Vanda Pharmaceuticals (VNDA) Gross Margin (2016 - 2025)

Historic Gross Margin for Vanda Pharmaceuticals (VNDA) over the last 13 years, with Q4 2025 value amounting to 93.3%.

  • Vanda Pharmaceuticals' Gross Margin fell 18300.0% to 93.3% in Q4 2025 from the same period last year, while for Dec 2025 it was 93.96%, marking a year-over-year decrease of 3400.0%. This contributed to the annual value of 93.96% for FY2025, which is 3400.0% down from last year.
  • Per Vanda Pharmaceuticals' latest filing, its Gross Margin stood at 93.3% for Q4 2025, which was down 18300.0% from 94.75% recorded in Q3 2025.
  • Vanda Pharmaceuticals' 5-year Gross Margin high stood at 95.13% for Q4 2024, and its period low was 90.3% during Q3 2021.
  • Its 5-year average for Gross Margin is 92.29%, with a median of 92.36% in 2023.
  • As far as peak fluctuations go, Vanda Pharmaceuticals' Gross Margin soared by 27700bps in 2024, and later tumbled by -18300bps in 2025.
  • Vanda Pharmaceuticals' Gross Margin (Quarter) stood at 90.83% in 2021, then fell by -1bps to 90.33% in 2022, then grew by 2bps to 92.36% in 2023, then increased by 3bps to 95.13% in 2024, then fell by -2bps to 93.3% in 2025.
  • Its Gross Margin was 93.3% in Q4 2025, compared to 94.75% in Q3 2025 and 94.8% in Q2 2025.